Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Phase 2a Study To Assess the Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza, Via a Human Viral Challenge Model in Healthy Adult Participants

NCT05507567 is registered in ClinicalTrials.gov with Pneumagen Ltd. as lead sponsor.

NCT NCT05507567
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05507567 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Phase 2a Study To Assess the Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza, Via a Human Viral Challenge Model in Healthy Adult Participants
Lead sponsor
Pneumagen Ltd.
Phase
Phase 2
Overall status
Completed
Start date
August 12, 2022
Completion date
May 4, 2023
Enrollment
104 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

influenza viral infections